ArticleBioinformatics (Oxford, England)2021
Optimizing blood-brain barrier permeation through deep reinforcement learning for de novo drug design.
Article in Bioinformatics (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Application of Reinforcement Learning Techniques in De Novo Drug Design: A Systematic Literature Review.Health science reports · 2026Article
- Peptide-functionalized nanoparticles for brain-targeted therapeutics.Drug delivery and translational research · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- A systematic review of deep learning chemical language models in recent era.Journal of cheminformatics · 2024Review
- The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.Molecular therapy. Nucleic acids · 2024Review
- Advancing Central Nervous System Drug Delivery with Microtubule-Dependent Transcytosis of Novel Aqueous Compounds.Biomaterials research · 2024Article
- A comprehensive review of artificial intelligence for pharmacology research.Frontiers in genetics · 2024Review
- Challenges in Permeability Assessment for Oral Drug Product Development.Pharmaceutics · 2023Review
- Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods.Journal of chemical information and modeling · 2023Review
- Machine Learning Methods for Small Data Challenges in Molecular Science.Chemical reviews · 2023Review
- De novo drug design based on Stack-RNN with multi-objective reward-weighted sum and reinforcement learning.Journal of molecular modeling · 2023Article
- Computer-aided multi-objective optimization in small molecule discovery.Patterns (New York, N.Y.) · 2023Review
- Conditional reduction of the loss value versus reinforcement learning for biassing a de-novo drug design generator.Journal of cheminformatics · 2022Article
- Designing optimized drug candidates with Generative Adversarial Network.Journal of cheminformatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
motivationThe process of placing new drugs into the market is time-consuming, expensive and complex. The application of computational methods for designing molecules with bespoke properties can contribute to saving resources throughout this process. However, the fundamental properties to be optimized are often not considered or conflicting with each other. In this work, we propose a novel approach to consider both the biological property and the bioavailability of compounds through a deep reinforcement learning framework for the targeted generation of compounds. We aim to obtain a promising set of selective compounds for the adenosine A2A receptor and, simultaneously, that have the necessary properties in terms of solubility and permeability across the blood-brain barrier to reach the site of action. The cornerstone of the framework is based on a recurrent neural network architecture, the Generator. It seeks to learn the building rules of valid molecules to sample new compounds further. Also, two Predictors are trained to estimate the properties of interest of the new molecules. Finally, the fine-tuning of the Generator was performed with reinforcement learning, integrated with multi-objective optimization and exploratory techniques to ensure that the Generator is adequately biased.
resultsThe biased Generator can generate an interesting set of molecules, with approximately 85% having the two fundamental properties biased as desired. Thus, this approach has transformed a general molecule generator into a model focused on optimizing specific objectives. Furthermore, the molecules' synthesizability and drug-likeness demonstrate the potential applicability of the de novo drug design in medicinal chemistry. AVAILABILITY AND IMPLEMENTATION: All code is publicly available in the https://github.com/larngroup/De-Novo-Drug-Design. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.